Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Wu, Jen-Hao; Pennesi, Edoardo; Bautista, Francisco; Garrett, May; Fukuhara, Kei; Brivio, Erica; Ammerlaan, Anneke C. J.; Locatelli, Franco; van der Sluis, Inge M.; Rossig, Claudia; Chen-Santel, Christiane; Bielorai, Bella; Petit, Arnaud; Starý, Jan; Díaz-de-Heredia, Cristina; Rives, Susana; O’Marcaigh, Aengus; Rizzari, Carmelo; Engstler, Gernot; Nysom, Karsten; Rubio-San-Simón, Alba; Bruno, Benedicte; Bertrand, Yves; Brethon, Benoît; Rialland, Fanny; Plat, Geneviève; Dirksen, Uta; Sramkova, Lucie; Zwaan, C. Michel; Huitema, Alwin D. R.

doi:10.1007/s40262-024-01386-z

3979Accesses
7Citations
1Altmetric
0Mentions

Metrics

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Last updated: Fri, 14 Aug 2026 5:18:26 UTC

Accesses

Accesses is an approximate count of unique views and downloads. This number can fluctuate depending on multiple factors.

We update counts daily.

3979 Accesses

Citations

Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.

7Citations

Altmetric

2 tweeters
18 Mendeley

Altmetric calculates a score based on the online attention an article gets — the higher the score, the more online attention an article has received.

The donut visual summarises attention from different sources such as social media and news outlets. A breakdown is shown in the legend.

Older articles have had more time to get noticed, so Altmetric provides context data for articles of a similar age.

This article is in the 1^st percentile (ranked 123,695^th) of the 155,295 tracked articles of a similar age in all journals and the 1^st percentile (ranked 3^rd) of the 4 tracked articles of a similar age in Clinical Pharmacokinetics.

View more on Altmetric.

Back to article page